Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?
نویسنده
چکیده
Infectious diseases are among the main causes of death and disability in developing countries, and they are a major reason for the health disparity between rich and poor countries. One of the reasons for this public health tragedy is a lack of lifesaving essential medicines, which either do not exist or badly need improvements. In this article, we analyse which of the push and pull mechanisms proposed in the recent literature may serve to promote research into neglected infectious diseases. A combination of push programmes that subsidise research inputs through direct funding and pull programmes that reward research output rather than research input may be the appropriate strategy to stimulate research into neglected diseases. On the one hand, early-stage (basic) research should be supported through push mechanisms, such as research grants or publicly financed research institutions. On the other hand, pull mechanisms, such as prize funds that link reward payments to the health impacts of effective medicines, have the potential to stimulate research into neglected diseases.
منابع مشابه
Encouraging the development of new vaccines.
Investment in the development of new vaccines is suboptimal. Changing this situation requires a creative blend of "push" and "pull" strategies. One successful policy model is the Orphan Drug Act, whose key features include large research and development (R and D) tax credits as well as Food and Drug Administration (FDA) counseling and priority review. Such supply-side R and D incentive provisio...
متن کاملR&D Incentives for Neglected Diseases
Neglected diseases are typically characterized as those for which adequate drug treatment is lacking, and the potential return on effort in research and development (R&D), to produce new therapies, is too small for companies to invest significant resources in the field. In recent years various incentives schemes to stimulate R&D by pharmaceutical firms have been considered. Broadly speaking, th...
متن کاملPerspectives on stimulating industrial research and development for neglected infectious diseases.
This paper summarizes recent thinking on stimulating industrial research and development (R&D) for neglected infectious diseases and argues that it is critical to enlarge the value of the market for medicines and vaccines through, for example, global purchase funds. The most important economic barriers to R&D are that the commercial markets are small and that individual purchasing power is seve...
متن کاملLegislation governing the US incentive scheme for neglected diseases needs to be amended, urges MSF.
As amedical humanitarian organisation diagnosing and treating people with neglected diseases for almost 30 years, Médecins Sans Frontières (MSF) understands only too well that the dearth of research and development for new tools to treat these diseases is directly attributable to insufficient funding and incentives. Innovative incentive mechanisms for research and development, including “pull” ...
متن کاملIncreasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
1. Introduction 2. Economics of the pharmaceutical R&D process 2a. Costs and risks 2b. R&D returns 2c. The critical significance of patents in pharmaceuticals 3. The Orphan Drug Act of 1983 3a. Push and pull incentive programs 3b. Characteristics of the Orphan Drug Act 3c. Orphan drug designation and approvals 3d. Costs of orphan drugs 3e. Revenues from marketed orphan drugs 3f. Health benefits...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 8 شماره
صفحات -
تاریخ انتشار 2013